Prevalence of Clinical Strains of Enterobacteria With Reduced Susceptibility to Carbapenems in the North-West Region of France

NCT02799225 | Completed

• 1 other identifier: PHRCIR11-DR-MAMMERI
• Study Type: observational
• Target: 287
• Locations: 1 country
• Sites: 6

Brief Summary

Enterobacteria constitute a family of Gram negative bacilli of the gastrointestinal flora. These micro-organisms are frequently responsible for nosocomial or community-acquired infections, for which treatment is essentially based on the use of beta-lactam antibiotics. This class of antibiotics comprises penicillins, cephalosporins, monobactams and carbapenems. Carbapenems have the advantage of possessing a broad antibacterial spectrum and the capacity to resist the hydrolytic action of a large number of beta-lactamases, widespread inactivating enzymes. However, new enzymes, called carbapenemases, able to confer resistance to carbapenems either alone or in combination with additional resistance mechanisms such as loss of membrane permeability or overexpression of efflux systems, are currently emerging all over the world. Carbapenemases represent a major public health problem because of the risk of therapeutic impasse and their high epidemic potential.

Conditions

Enterobacteriaceae

Keywords

carbapenems

Outcome Measures

Primary Outcomes (1)

• prevalence of clinical strains of Enterobacteria

  1 year

Secondary Outcomes (1)

• characterization of the mechanisms responsible for carbapenems resistance

  1 year

Study Arms (1)

Enterobacteria

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients undergoing bacteriological samples as part of routine clinical practice during their hospital stay in one of the 6 participating centres. Patients in whom the results of bacteriological examinations reveal the presence of an Enterobacteria strain with reduced susceptibility to carbapenems will be included in this project

You may qualify if:

• Patients in whom the results of bacteriological examinations reveal the presence of an Enterobacteria strain with reduced susceptibility to carbapenems
• Control : patients ( infected or colonized ) a strain of Enterobacter sensitive to carbapenems immediately isolated after a strain of Enterobacter having decreased susceptibility to carbapenems from the same service and same hospital ( 2 strains susceptible strain with reduced sensitivity).

You may not qualify if:

• Duplicate : same strain to a first strain of reduced sensitivity in isolated the same patient during the study period ( same bacterial species , even after characterization resistance mechanism).

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (6)

CH Abbeville

Abbeville, 80142, France

Location

CHU Amiens

Amiens, 80054, France

Location

CH Beauvais

Beauvais, 60021, France

Location

CHU Caen

Caen, 14033, France

Location

CHU Compiegne

Compiègne, 60321, France

Location

CHRU Lille

Lille, 59037, France

Location

Related Publications (3)

• Dupont H, Choinier P, Roche D, Adiba S, Sookdeb M, Branger C, Denamur E, Mammeri H. Structural Alteration of OmpR as a Source of Ertapenem Resistance in a CTX-M-15-Producing Escherichia coli O25b:H4 Sequence Type 131 Clinical Isolate. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e00014-17. doi: 10.1128/AAC.00014-17. Print 2017 May.

  PMID: 28264855 RESULT

• Dupont H, Gaillot O, Goetgheluck AS, Plassart C, Emond JP, Lecuru M, Gaillard N, Derdouri S, Lemaire B, Girard de Courtilles M, Cattoir V, Mammeri H. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations. Antimicrob Agents Chemother. 2015 Oct 19;60(1):215-21. doi: 10.1128/AAC.01559-15. Print 2016 Jan.

  PMID: 26482307 RESULT

• Ammenouche N, Dupont H, Mammeri H. Characterization of a novel AmpC beta-lactamase produced by a carbapenem-resistant Cedecea davisae clinical isolate. Antimicrob Agents Chemother. 2014 Nov;58(11):6942-5. doi: 10.1128/AAC.03237-14. Epub 2014 Aug 18.

  PMID: 25136020 RESULT

Study Officials

• Hedi MAMMERI, PhD

  CHU Amiens

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 10, 2016
• First Posted: June 14, 2016
• Study Start: June 1, 2012
• Primary Completion: February 2, 2014
• Study Completion: February 2, 2014
• Last Updated: April 27, 2026

Record last verified: 2026-04

Locations

FR (6)